Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | VNN1 | O95497 | 5/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.44 |
| ▸ | CLK1 | P49759 | 2/20 | 0.44 |
| ▸ | CLK2 | P49760 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2392295 | 0.82 | VNN1 (0.62) | MAPTNPC1RAB9AMEN1GAA | |
| SCHEMBL18571985 | 0.80 | MEN1 (0.52) | MAPTNPC1RAB9AMEN1GAA | |
| SCHEMBL29911298 | 0.80 | MEN1 (0.52) | MAPTNPC1RAB9AMEN1GAA | |
| SCHEMBL30236327 | 0.79 | EGFR (0.51) | MAPTNPC1RAB9AMEN1GAA | |
| SCHEMBL27103118 | 0.79 | EGFR (0.51) | MAPTNPC1RAB9AMEN1GAA | |
| SCHEMBL31390123 | 0.76 | P2RX3 (0.40) | MAPT | |
| SCHEMBL26679920 | 0.76 | P2RX3 (0.40) | MAPT | |
| SCHEMBL16667695 | 0.75 | ALDH1A1 (0.52) | MAPTDYRK1BALDH1A1SMN1; SMN2 | |
| SCHEMBL26165530 | 0.75 | DYRK1B (0.40) | DYRK1BSMN1; SMN2 | |
| SCHEMBL12675592 | 0.75 | MEN1 (0.54) | MAPTNPC1RAB9AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667634-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667634-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| WO-2020227020-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667634-B2 | Inhibitors of RAF kinases | BRAF, RAF1, NRAS | MAPT 3066/4885NPC1 1495/4885RAB9A 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.